NYSCF and Janssen Partner on Neurodegenerative Disease Drug Discovery
The New York Stem Cell Foundation Research Institute (NYSCF) and Janssen Research & Development, a Johnson & Johnson company, have partnered to accelerate the development of precision medicines for neurodegenerative diseases. NYSCF’s AI-powered platform, using automated stem cell systems, will be leveraged to identify new drug targets and therapies. This collaboration combines NYSCF’s expertise in stem cell […]
BioCentriq Expands Cell Therapy Manufacturing
This exciting news in the cell therapy sector could revolutionize how quickly life-changing therapies reach patients. BioCentriq, a leading cell therapy contract development and manufacturing organization (CDMO), is set to expand its operations and establish a cutting-edge cell therapy manufacturing facility in Princeton, New Jersey. This facility will become BioCentriq’s new headquarters, marking a significant […]
Promising Phase 1 Results for Hemophilia A Gene Therapy
Expression Therapeutics announced promising Phase 1 clinical trial results for its novel gene therapy, ET3, treating hemophilia A. The trial, detailed in the New England Journal of Medicine, showed significant increases in Factor VIII levels and a reduction in bleeding events in participants with severe hemophilia A. The therapy uses a lentiviral vector targeting hematopoietic stem […]
FDA Grants Breakthrough Therapy Designation to Seres’ SER-155
Seres Therapeutics announced that the FDA granted Breakthrough Therapy designation to SER-155, their lead investigational drug, for reducing bloodstream infections in adults undergoing stem cell transplants. This designation is based on positive Phase 1b clinical trial data showing a significant reduction in infections compared to a placebo. A meeting with the FDA to discuss the […]
Eterna Therapeutics Investigates ERNA-101 in Cancer Models
Eterna Therapeutics, a preclinical-stage company, announced a research collaboration with MD Anderson Cancer Center to evaluate its lead induced mesenchymal stem cell therapy, ERNA-101, for treating ovarian and breast cancers. ERNA-101, a proprietary allogenic cell therapy, aims to stimulate antitumor immunity. The research will assess ERNA-101’s effects both in vitro and in vivo, with potential future studies exploring […]
FDA Approves StemCyte’s REGENECYTE™ Cord Blood Therapy
StemCyte Inc. announced FDA approval of its REGENECYTE™ cord blood stem cell therapy for treating blood and immune system disorders, making them the first U.S.-based biotech company to receive such a biologics license for this therapy in 2024. REGENECYTE™ is an allogeneic therapy derived from umbilical cord blood. The company is also exploring other applications […]
BioRestorative Therapies Expands Stem Cell Research with New York State License
In a significant advancement for regenerative medicine, BioRestorative Therapies, Inc. has secured a provisional license from the New York State Department of Health (NYSDOH) to process allogeneic (non-autologous) donor tissue material, including stem cells, for medical research. This expansion builds upon their previous authorization, which was limited to autologous (self-donated) mesenchymal stem cells. This new […]
Pioneering Stem Cell Therapy Shows Promise in Alzheimer’s Treatment: Regeneration Biomedical Releases First Cohort Results
In a breakthrough for Alzheimer’s disease research, Regeneration Biomedical, Inc. recently presented promising findings from a Phase I clinical trial that delivers stem cell therapy directly into the brains of patients. Utilizing Wnt-activated, autologous, expanded, adipose-derived stem cells (RB-ADSCs), the therapy is designed to potentially slow or reverse the progression of Alzheimer’s. These specialized stem […]
Revolutionary Stem Cell Therapy: New Partnership Aims to Transform Orthopedic Treatments for Rotator Cuff Injuries
In an exciting leap for stem cell research and regenerative medicine, Regenerative Orthopedics & Sports Medicine (ROSM) has joined forces with Orthobiologics Research Initiative Inc. (ORI) in a groundbreaking study funded by the Maryland Stem Cell Research Fund. This innovative research, set for completion by December 2026, focuses on harnessing the healing potential of microfat […]
Factor Bioscience and Eterna Therapeutics Partner to Accelerate Advanced Cell Therapies for Cancer, Rare Diseases, and Autoimmune Disorders
In a groundbreaking collaboration that promises to reshape the future of medicine, Factor Bioscience and Eterna Therapeutics have announced an exclusive license agreement to accelerate the development of stem cell-based therapies for oncology, autoimmune disorders, and rare diseases. The agreement is centered around the utilization of Factor’s proprietary induced pluripotent stem cell (iPSC) technologies, which […]